Video

CAR T-Cell Therapy as Second-Line Treatment in LBCL

Author(s):

Manali Kamdar, MD,Matthew A. Lunning, DO, FACP

Matthew Lunning, DO, FACP, discusses the role of CAR T-cell therapy in the second-line treatment of large B-cell lymphoma (LBCL).

Related Videos
Armin Ghobadi, MD, professor, medicine, Oncology, Section of Bone Marrow Transplant; clinical director, Center for Gene and Cellular Immunotherapy, Siteman Cancer Center, Washington University
Tom van Meerten, MD, PhD, hematologist, Department of Hematology, University Medical Center Groningen
Lori A Leslie, MD
Andrew Ip, MD
Grzegorz S. Nowakowski, MD, and Samuel Yamshon, MD, break down the current treatment landscape for relapsed/refractory follicular lymphoma.
Amer Zeidan, MBBS, and Guillermo Garcia-Manero, MD, discuss current treatment trends in myelodysplastic syndromes.
Javier Pinilla, MD, PhD, and Talha Badar, MBBS, MD, discuss factors that influence later-line treatment choices in chronic myeloid leukemia.
Javier Pinilla, MD, PhD, and Talha Badar, MBBS, MD, on the implications of the FDA approval of asciminib in newly diagnosed CP-CML.
Dasom (Caroline) Lee, MD
Nosha Farhadfar, MD, and Chandler Park, MD, FACP
Related Content
FDA
January 16th 2025

Lete-Cel Receives FDA Breakthrough Therapy Designation for Advanced Myxoid/Round Cell Liposarcoma

Matthew Lunning, DO, FACP
December 21st 2023

Lunning and Mehta-Shah Unpack Treatment Needs and Future Directions in PTCL

Multiple Myeloma | stock.adobe.com
January 6th 2025

Anito-Cel Demonstrates Safety and Early Efficacy in R/R Multiple Myeloma

Matthew Lunning, DO, FACP
October 30th 2023

Lunning and Nastoupil Highlight Treatment Considerations and Ongoing Research in Follicular Lymphoma

Smoldering Myeloma
December 11th 2024

Cilta-Cel Leads to 100% MRD-Negativity Rate in High-Risk Smoldering Multiple Myeloma

Axi-Cel Sustains Long-Term Efficacy in R/R Follicular Lymphoma and MZL
December 10th 2024

Axi-Cel Sustains Long-Term Efficacy in R/R Follicular Lymphoma and MZL